Abstract
There is increasing evidence of the usefulness of electroencephalography (EEG) as an early neurophysiological marker of preclinical AD. Our objective was to apply machine learning approaches on event-related oscillations to discriminate preclinical AD from neurotypical controls. Twenty-two preclinical AD participants who were cognitively normal with elevated amyloid and 21 cognitively normal with no elevated amyloid controls completed n-back working memory tasks (n= 0, 1, 2). EEG signals were recorded through a high-density sensor net. The event-related spectral changes were extracted using the discrete wavelet transform in the delta, theta, alpha, and beta bands. The support vector machine (SVM) machine learning method was employed to classify participants, and classification performance was assessed using the Area Under the Curve (AUC) metric. The relative power of the beta and delta bands outperformed other frequency bands with higher AUC values. The 2-back task obtained higher AUC values than the 0 and 1-back tasks. The highest AUC values were from the 2-back task beta band (AUC = 0.86) and delta bands (AUC = 0.85) nontarget data. This study demonstrates the promise of using machine learning on EEG event-related oscillations from working memory tasks to detect preclinical AD.
- Alzheimer’s disease (AD)
- preclinical
- spectral analysis
- electroencephalography (EEG)
- discrete wavelet transform (DWT)
- machine learning
- working memory
- event-related oscillations (ERO)
- area under the receiver operating characteristic curve (AUC)
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was completed at the Hoglund Biomedical Imaging Center which is supported by the Forrest and Sally Hoglund and a High-End Instrumentation grant from the National Institutes of Health (S10 RR29577). Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number K01 AG058785 and P30 AG072973. This study was supported in part by a pilot grant of the KU Alzheimer Disease Research Center (P30 AG035982). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of University of Kansas Medical Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
